US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
On Thursday, Viatris Inc. (NASDAQ:VTRS) reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis.
周四，维亚特里斯公司（纳斯达克股票代码：VTRS）公布的第二季度收入为37.97亿美元，略高于市场预期的37.77亿美元，按剥离调整后的运营基础上增长约2％。
Brands net sales reached $2.36 billion, reflecting strong growth in Greater China and the expansion of the company's portfolio in Emerging Markets and JANZ, partially offset by unfavorable channel dynamics in North America and the impact of government price regulations in Japan and Australia.
该品牌的净销售额达到23.6亿美元，这反映了大中华区的强劲增长以及该公司在新兴市场和JANZ的投资组合的扩大，但北美不利的渠道动态以及日本和澳大利亚政府价格监管的影响部分抵消了这一点。
Related: Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs.
相关信息：诺华和维亚特里斯因非法使用用于癌症治疗药物的HeLa细胞而被起诉。
Generic net sales of $1.42 billion reflect strong growth from new product launch performances in Developed Markets, continued growth from complex products, and solid performance across the broader European portfolio.
仿制药净销售额为14.2亿美元，反映了发达市场新产品发布业绩的强劲增长、复杂产品的持续增长以及更广泛的欧洲产品组合的稳健表现。
The company generated approximately $210 million in new product revenues, primarily driven by Breyna, lisdexamfetamine, and other new products globally.
该公司创造了约2.1亿美元的新产品收入，主要是由Breyna、lidexamfetamine和全球其他新产品推动的。
The company reported adjusted EPS of $0.69, down 8% year over year, beating the consensus of $0.68.
该公司报告调整后的每股收益为0.69美元，同比下降8％，超过市场预期的0.68美元。
"I am pleased to report strong second quarter results in which we delivered divestiture-adjusted operational revenue growth across all segments, including strong growth in Greater China. This represents our fifth consecutive quarter of divestiture-adjusted operational revenue growth and demonstrates our ability to execute and grow our base business," said Scott Smith, CEO.
“我很高兴地报告第二季度业绩强劲，我们在所有细分市场实现了经剥离调整后的运营收入增长，包括大中华区的强劲增长。这是我们连续第五个季度实现经剥离调整后的运营收入增长，也表明了我们执行和发展基础业务的能力。” 首席执行官斯科特·史密斯说。
Guidance: Viatris says strong year-to-date performance gives it confidence in raising its outlook to approximately $500 million to $600 million in new product revenues in 2024 from prior range of $450 million to $550 million.
指导方针：维亚特里斯表示，今年迄今为止的强劲表现使其有信心将其2024年新产品收入前景从之前的4.5亿美元至5.5亿美元上调至约5亿至6亿美元。
Viatris expects 2024 sales of $14.6 billion – $15.1 billion versus the prior guidance of $14.98 billion – $15.48 billion and consensus of $14.956 billion.
维亚特里斯预计，2024年的销售额为146亿美元至151亿美元，而之前的预期为149.8亿美元至154.8亿美元，共识为149.56亿美元。
The company expects 2024 adjusted EPS of $2.58 – $2.73, versus the prior guidance of $2.66 – $2.81 and the consensus of $2.73.
该公司预计，2024年调整后的每股收益为2.58美元至2.73美元，而之前的预期为2.66美元至2.81美元，共识为2.73美元。
Price Action: VTRS stock is up 5.33% at $11.97 at last check Thursday.
价格走势：周四最后一次检查时，VTRS股价上涨5.33％，至11.97美元。
Illustration of Phrama lab worker created with MidJourney.
使用 MidJourney 创作的 Phrama 实验室工作人员的插图。
- GoodRx Reports Q2 Earnings With Increased Prescription Revenue But Subscription Challenges.
- GoodRx公布第二季度收益，处方收入增加，但订阅面临挑战。